Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | CCL5 | P13501 | 2/20 | 0.31 |
| ▸ | CCR5 | P51681 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17172981 | 0.91 | CCL5 (0.31) | HCRTR2CCL5 | |
| SCHEMBL24267436 | 0.85 | EPHX2 (0.33) | HCRTR2CCL5 | |
| SCHEMBL22171140 | 0.85 | EPHX2 (0.33) | HCRTR2CCL5 | |
| SCHEMBL10232856 | 0.85 | EPHX2 (0.33) | HCRTR2CCL5 | |
| SCHEMBL12202151 | 0.82 | TSHR (0.37) | HCRTR2 | |
| SCHEMBL824146 | 0.80 | EPHX2 (0.39) | HCRTR2CCL5 | |
| SCHEMBL20233006 | 0.78 | EPHX2 (0.35) | HCRTR2CCL5 | |
| SCHEMBL22893218 | 0.77 | USP30 (0.31) | HCRTR2 | |
| SCHEMBL8077317 | 0.76 | TSHR (0.37) | HCRTR2 | |
| SCHEMBL21025379 | 0.74 | POLB (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2023-01-19 | — | — | US | disclosed |
| US-10954202-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | ABBVIE INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | HCRTR2 3771/4885CCL5 3510/4885CCR5 3184/4885 |
| US-10954202-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PTPN1, PTPN2, PTPN18 | HCRTR2 3771/4885CCL5 3510/4885CCR5 3184/4885 |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | HCRTR2 2521/4885CCL5 1396/4885CCR5 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.